Insulin glulisine
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | APIDRA SOLOSTAR | — | 2007-04-12 – 2008-10-24 | fda.gov ↗ |
| Approved | EU (EMA) | Apidra | — | 2004-09-27 | europa.eu ↗ |
| Approved | US (FDA) | APIDRA SOLOSTAR | — | 2004-04-16 | fda.gov ↗ |
Trials 66 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials · 1 met primary | ||||||
| Phase 1 | NCT02432716 | Apr 2015 → Oct 2018 | Down syndrome | HealthPartners Institute | Completed | No outcome recorded |
| Phase 1 | NCT00979875 | Sep 2009 → Feb 2010 | — | Halozyme Therapeutics | Completed | Met primary |
| Phase 1 | NCT01159353 | Sep 2007 → Apr 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00824668 | Aug → Oct 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00310297 | Nov → Dec 2004 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00297583 | Apr → May 2004 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00311077 | Apr → Oct 2004 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00368394 | Jan 2004 → ? | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00290043 | Dec 2001 → Mar 2002 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02503501 | Sep 2015 → Feb 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | HealthPartners Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01436045 | Sep 2011 → Jun 2013 | Alzheimer disease | HealthPartners Institute | Completed | Met primary |
| Phase 318 trials · 4 met primary | ||||||
| Phase 3 | NCT00943709 | May 2009 → Mar 2010 | hyperglycemia, leukemia | University of Medicine and Dentistry of New Jersey | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00467376 | Jan 2007 → Jun 2008 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00562133 | Dec 2006 → Mar 2007 | type 2 diabetes mellitus | IKFE Institute for Clinical Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT00272064 | Oct 2005 → May 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00135941 | Aug 2005 → Sep 2007 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00115570 | Apr 2005 → Nov 2006 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00397553 | Jan 2005 → Dec 2007 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00174642 | Dec 2004 → Dec 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00290979 | Dec 2004 → ? | type 1 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00174668 | Nov 2004 → Nov 2007 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00545337 | Sep 2004 → Jun 2005 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00546702 | Sep 2004 → Feb 2005 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00135083 | Aug 2004 → Nov 2007 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00135096 | Aug 2004 → Jul 2007 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00272012 | Jul 2004 → Sep 2006 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00135057 | Apr 2004 → Aug 2005 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00290927 | Dec 2003 → ? | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00046150 | May → Dec 2002 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 435 trials · 5 met primary · 2 missed | ||||||
| Phase 4 | NCT04019821 | Jan 2020 → Jan 2023 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04157738 | Nov 2019 → Dec 2020 | type 1 diabetes mellitus | Emory University | Completed | Met primary |
| Phase 4 | NCT03328845 | Jan 2017 → Nov 2020 | type 1 diabetes mellitus | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Completed | No outcome recorded |
| Phase 4 | NCT02987751 | Dec 2016 → Sep 2018 | type 2 diabetes mellitus | India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals | Completed | No outcome recorded |
| Phase 4 | NCT02914886 | Sep 2016 → Apr 2019 | localized lipodystrophy, type 1 diabetes mellitus | Kinderkrankenhaus auf der Bult | Completed | Met primary |
| Phase 4 | NCT02276859 | Oct 2014 → Sep 2015 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT02333851 | Jun 2013 → Feb 2014 | type 2 diabetes mellitus | Hospital Universitario Central de Asturias | Terminated | No outcome recorded |
| Phase 4 | NCT01234597 | Dec 2012 → Apr 2015 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02048189 | Mar 2012 → Feb 2015 | — | Centre Hospitalier Universitaire Dijon | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01889914 | Jan 2012 → Mar 2015 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Unknown | No outcome recorded |
| Phase 4 | NCT01500850 | Oct 2011 → Oct 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01678235 | Sep 2011 → Sep 2012 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | Missed primary |
| Phase 4 | NCT01417897 | Sep 2011 → May 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01202474 | May 2011 → Oct 2012 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01203111 | Dec 2010 → Jul 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01204593 | Nov 2010 → Jan 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01212913 | Aug 2010 → May 2012 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT01122979 | Jul 2010 → Oct 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01087567 | Jul 2010 → Jan 2014 | type 2 diabetes mellitus | Ohio University | Completed | No outcome recorded |
| Phase 4 | NCT01081938 | Feb 2010 → Feb 2011 | type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00979628 | Jan 2010 → Mar 2012 | hyperglycemia, type 2 diabetes mellitus | Guillermo Umpierrez, MD | Completed | No outcome recorded |
| Phase 4 | NCT01079364 | Jan 2010 → Jul 2012 | type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01013571 | Oct 2009 → Jan 2012 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT00964574 | Jul 2009 → Jul 2010 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00965549 | Jul 2009 → Dec 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02278913 | Apr 2009 → Apr 2010 | diabetes mellitus, hyperglycemia | Universidad Nacional de Asunción | Completed | No outcome recorded |
| Phase 4 | NCT00607087 | Jan 2008 → Jun 2009 | type 1 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase 4 | NCT00590044 | Dec 2007 → Jun 2008 | diabetic ketoacidosis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00596687 | Dec 2007 → Dec 2009 | hyperglycemia, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00526513 | Jul 2007 → May 2008 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00474838 | Apr 2007 → Aug 2012 | type 2 diabetes mellitus | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00539448 | Apr 2007 → Dec 2008 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00360698 | Jul 2006 → Aug 2008 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT00384085 | May 2006 → Mar 2010 | type 2 diabetes mellitus | Sanofi | Completed | Mixed |
| Phase 4 | NCT00489190 | Aug 2005 → ? | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT00467636 | Jul 2007 → May 2009 | chronic obstructive pulmonary disease, hyperglycemia | The Royal Bournemouth Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy40 trials | ||||||
| Phase 1 | NCT00969592 Comparator | Nov → Dec 2007 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02846831 Comparator | Jan 2019 → Jan 2020 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02488616 Comparator | Mar → Nov 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02490098 Comparator | Jan → Jul 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02798250 Comparator | Jun 2016 → Mar 2017 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02626936 Comparator | Jan → Jun 2016 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01662921 Comparator | Apr 2013 → Jan 2015 | gestational diabetes | Sansum Diabetes Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01194258 Background | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 2 | NCT01194245 Background | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 2 | NCT02846857 Comparator | ? → Jul 2019 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT07070752 Comparator | Apr → Nov 2023 | type 1 diabetes mellitus | Geropharm | Completed | No outcome recorded |
| Phase 3 | NCT04974528 Comparator | Sep 2021 → Oct 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03529123 Background | Jun 2018 → Nov 2019 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01768559 Comparator | Jan 2013 → Dec 2014 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT01792830 Comparator | Oct 2012 → Feb 2014 | glucose metabolism disease | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT00670228 Comparator | Apr 2008 → Nov 2009 | — | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00271284 Background | Oct 2005 → Sep 2008 | type 1 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT04124302 Background | Oct 2019 → Mar 2024 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT03359837 Background | Jan 2018 → Jun 2020 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03260868 Background | Sep 2017 → Nov 2018 | type 1 diabetes mellitus | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02688933 Background | May 2016 → Jun 2017 | type 1 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase 4 | NCT02685449 Comparator | Feb 2016 → Feb 2018 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT03112538 Comparator | Jan 2016 → Dec 2018 | type 2 diabetes mellitus | Clinical Research Centre, Malaysia | Unknown | No outcome recorded |
| Phase 4 | NCT02276196 Comparator | Sep 2014 → Apr 2016 | diabetes mellitus, diabetic kidney disease | Amsterdam UMC, location VUmc | Completed | Missed primary |
| Phase 4 | NCT01848990 Background | Mar 2013 → Feb 2014 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01524705 Comparator | Aug 2012 → Jul 2014 | type 2 diabetes mellitus | University of Washington | Completed | Met primary |
| Phase 4 | NCT01594060 Comparator | Jun 2012 → Oct 2014 | type 2 diabetes mellitus | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT01131052 Comparator | Mar 2011 → Dec 2013 | hyperglycemia, type 2 diabetes mellitus | Guillermo Umpierrez | Completed | No outcome recorded |
| Phase 4 | NCT01143948 Comparator | Jan → Apr 2011 | cirrhosis of liver, type 2 diabetes mellitus | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT01121835 Background | Feb 2010 → Mar 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00913497 Comparator | Jun 2009 → Jan 2012 | type 1 diabetes mellitus | Corewell Health West | Completed | No outcome recorded |
| Phase 4 | NCT00467649 Comparator | May 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 4 | NCT00283049 Background | Feb 2006 → Nov 2008 | type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT00394407 Comparator | Sep 2005 → Jun 2006 | hyperglycemia, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT01621776 Comparator | Jun 2011 → Aug 2012 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT01855243 Comparator | Mar 2010 → Feb 2014 | type 2 diabetes mellitus | Cairo University | Completed | No outcome recorded |
| — | NCT00528918 Comparator | Jun 2007 → May 2011 | type 2 diabetes mellitus | Carl T. Hayden VA Medical Center | Completed | No outcome recorded |
| — | NCT00927524 Comparator | Apr 2005 → Apr 2006 | type 1 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-06-28 | Halozyme Therapeutics | Results Coinjection of Halozyme's rHuPH20 Enzyme Accelerates the Absorption and Action of Mealtime Insulin Analogs halozyme.com ↗
The coinjection of PH20 with lispro (Humalog(R)), aspart (NovoLog(R)) and glulisine (Apidra(R)) results in a more physiologic fast-in, fast-out profile and enhances the glucodynamic performance for each analog. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-06-28 | Halozyme Therapeutics | Coinjection of Halozyme's rHuPH20 Enzyme Accelerates the Absorption and Action of Mealtime Insulin Analogs halozyme.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Glulisine | “Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes...” NCT00546702 ↗77“Beginning 24 hours after maintenance of oral or enteral feedings patients receive an intensive regimen of insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4...” NCT00943709 ↗ “Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart)” NCT03112538 ↗ “Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening.” NCT02688933 ↗ “Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.” NCT04974528 ↗ “supporting its use as a biosimilar insulin glulisine” PMID 41366610 ↗ Dec 2025 “Insulin Glulisine (HMR1964) Injected Subcutaneously” NCT00545337 ↗ “insulin glargine insulin glulisine” NCT00474838 ↗ “Apidra (insulin glulisine)” NCT00979628 ↗ |
| Known as | Apidra | “This study will compare how well regular insulin will compare to glargine (Lantus®) once daily plus glulisine (Apidra®) insulin before meals in hospitalized patients with type...” NCT00394407 ↗24“Beginning 24 hours after maintenance of oral or enteral feedings patients receive an intensive regimen of insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4...” NCT00943709 ↗ “Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects” NCT00311077 ↗ “pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.” NCT00135096 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])” NCT00467649 ↗ |
| Known as | Apidra (insulin glulisine) | “Apidra (insulin glulisine)” NCT00979628 ↗ |
| Known as | glulisine | “Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus...” NCT02333851 ↗22“The rapid-acting insulin analogue insulin glulisine (glulisine) was compared with insulin lispro (lispro) for efficacy and safety in Japanese patients with type 1 diabetes...” PMID 19614947 ↗ Jul 2009 “The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day)” NCT04196231 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.” NCT01087567 ↗ “To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs” PMID 19614946 ↗ Jul 2009 |
| Known as | HMR1964 | “Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes...” NCT00546702 ↗8“Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group,...” NCT00290979 ↗ “Dose-Exposure-Response Relationship of Insulin Glulisine (HMR1964) in Subjects With Type 1 Diabetes Mellitus Assessed With the Euglycemic Clamp Technique Using the Biostator (TM)” NCT00368394 ↗ “insulin glulisine (HMR 1964)” NCT00545337 ↗ “INSULIN GLULISINE (HMR1964)” NCT00964574 ↗ “Insulin glulisine (HMR1964)” NCT00046150 ↗ “INSULIN GLULISINE (HMR1964)” NCT01234597 ↗ “Insulin Glulisine (HMR1964)” NCT03529123 ↗ “Apidra glulisine (HMR1964)” NCT00489190 ↗ |
| Known as | insulin, glulisine, Apidra | “insulin, glulisine, Apidra” NCT02432716 ↗ |
| Known as | Insuline glulisine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00545337 ↗ |
| Modality | Protein / enzyme biologic | “The rapid-acting insulin analogue insulin glulisine” PMID 19614947 ↗ Jul 2009 |
| Route | Subcutaneous | “Continuous Subcutaneous Insulin Infusion (CSII)” NCT00046150 ↗ |